Hence, combining mTOR inhibitors with different drugs targeting other signaling pathways is a much more effective therapeutic approach against GBM, as it improves responses to therapy, overcomes therapy resistance, and addresses GBM heterogeneity. Here, MTOR is linked to glioblastoma.